[{"id":"67c8cf1c-10de-492c-b487-6be1c0e1cff9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395260","created_at":"2022-05-27T11:56:25.157Z","updated_at":"2024-07-02T16:36:05.163Z","phase":"Phase 1","brief_title":"FL- 101 Study in Non-Metastatic MIBC","source_id_and_acronym":"NCT05395260","lead_sponsor":"Flame Biosciences","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FL-101"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/22/2022","start_date":" 08/22/2022","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-08-19"},{"id":"3aae4a72-17aa-4ae7-b12d-0acae1fabb95","acronym":"","url":"https://clinicaltrials.gov/study/NCT04758949","created_at":"2021-02-17T14:01:03.886Z","updated_at":"2024-07-02T16:36:18.676Z","phase":"Phase 2","brief_title":"FL-101 in Surgically Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04758949","lead_sponsor":"Flame Biosciences","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • FL-101"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 12/22/2021","primary_completion_date":" 12/22/2021","study_txt":" Completion: 12/22/2021","study_completion_date":" 12/22/2021","last_update_posted":"2022-01-11"}]